News

Vietnam Investment Review on MSN6d
Akeso's first bispecific ADC enters clinical trials, advancing ‘IO+ADC’ 2.0 strategy
HONG KONG, July 3, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") has announced the successful ...
Oxford BioTherapeutics Announces Third Oncology Drug Candidate from Boehringer Ingelheim Collaboration Selected to Advance into IND-Enabling Studies
Drug candidate is one of several oncology assets approaching or in clinical development, discovered through Oxford ...
manilatimes7d
Akeso's First Bispecific ADC (Trop2/Nectin4 ADC) Enters Clinical Trials, Strengthening Leadership in 'IO+ADC' 2.0 Strategy - The Manila Times
HONG KONG, July 3, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') has announced the successful enrollment of the first patient in its Phase Ia clinical trial for AK146D1, a ...
Pharmabiz3d
Akeso enrols first patient in phase Ia trial for AK146D1, a bispecific ADC targeting Trop2 and Nectin4
Akeso enrols first patient in phase Ia trial for AK146D1, a bispecific ADC targeting Trop2 and Nectin4: Hong Kong Monday, July 7, 2025, 18:00 Hrs [IST] Akeso, Inc., a leading biop ...
BioSpace3d
Four Therapies Hanging On in Troubled TIGIT Space
TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...
The Manila Times8d
OSE Immunotherapeutics met à jour l’information sur les procédures en cours
OSE Immunotherapeutics provides an update on ongoing proceedings ...